A total of 44 Private Equity/Venture Financing deals (pending and completed) were announced in the Healthcare of the North America region, driven by Big Data, in the last twelve months resulting in a total deal value of over $3,013.9 million. In the LTM period, October 2021 turned out to be the most prolific in terms of deal size, with a total deal value of $839.4 million, resulting in an average deal value of $279.8 million during that month. On the other hand, the month of June 2021 was the most prolific in terms of deal volume, recording a total of 6 deals, resulting in an average deal value of $68.9 million during that month.
Of the 44 deals, the deal secured between Amgen Ventures LLC; Intermountain Ventures; McKesson Ventures; Merck Global Health Innovation Fund LLC; Northpond Ventures LLC; Pfizer Venture Investments; Population Health Partners LLC; The Carlyle Group Inc. and Saama Technologies Inc, was the largest Private Equity/Venture Financing deal in the North America Healthcare sector driven by Big Data, which was valued at $430.0 million and was completed on October 20, 2021. The second-largest deal was between Alexandria Venture Investments; Altitude Life Science Ventures; ARCH Venture Partners LP; Catalio Capital Management LP; F-Prime Inc; Invus Group LLC; Logos Global Management LLC; Mubadala Capital; Newpath Management LP; Polaris Partners LLC; re.Mind Capital; SoftBank Vision Fund II; Surveyor Capital Ltd; Waycross Ventures Ltd. and Neumora Therapeutics Inc, while the third-largest deal was between CVS Health Corp; Export Development Bank of Iran; General Atlantic LLC; Mass Mutual Ventures LLC; Openspace Ventures Pte. Ltd; Sequoia Capital LLP; SoftBank Vision Fund II and Biofourmis Inc. The Alexandria Venture Investments; Altitude Life Science Ventures; ARCH Venture Partners LP; Catalio Capital Management LP; F-Prime Inc; Invus Group LLC; Logos Global Management LLC; Mubadala Capital; Newpath Management LP; Polaris Partners LLC; re.Mind Capital; SoftBank Vision Fund II; Surveyor Capital Ltd; Waycross Ventures Ltd.-Neumora Therapeutics Inc deal and the CVS Health Corp; Export Development Bank of Iran; General Atlantic LLC; Mass Mutual Ventures LLC; Openspace Ventures Pte. Ltd; Sequoia Capital LLP; SoftBank Vision Fund II-Biofourmis Inc deal were valued at $400.0 million and $300.0 million, respectively. The fourth-largest deal was between B Capital Group Management, L.P.; Baidu Ventures; Bold Capital Partners; CITIC Industrial Investment Fund Management Co Ltd; Deerfield Management Co LP; Eight Roads Ventures; Formic Ventures; Lake Bleu Capital; Lilly Asia ventures; Maison Capital Group; Mirae Asset Capital Co Ltd; Orbimed Advisors LLC; Pavilion Capital Partners LLC; President International Development Corporation; Qiming Venture Partners; Sage Partners; Sequoia Capital China; Sinovation Ventures; Warburg Pincus LLC-InSilico Medicine valued at $255.0 million, whereas the deal between Avidity Partners LLC; BlackRock Inc; Pura Vida Investments LLC; RA Capital Management LP; Sands Capital Management LLC-eXo Imaging Inc valued at $220.0 million was the fifth-largest deal.
Cumulatively, the top five deals amounted to $1,605.0 million and accounted for nearly 53.25% of the total deals (by value) announced during the last twelve months. The North America region accounted for 70.81% of the total Private Equity/Venture Financing deals done globally, and accounted for 65.67% of the total deal size on a global scale.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
United States of America
Japan
Ireland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward